Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA methylation changes in hematologic malignancies: biologic and clinical implications

J P Issa1, S B Baylin, J G Herman

  • 1Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Leukemia
|March 1, 1997
PubMed
Summary

DNA methylation changes, particularly gene promoter hypermethylation, are common in human cancers like leukemia. This abnormality can be used for disease monitoring, minimal residual disease detection, and targeted therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1.

Oncogene·2026
Same author

Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.

Advances in cancer research·2016
Same author

A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.

Investigational new drugs·2014
Same author

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.

Oncogene·2013
Same author

Role of nuclear architecture in epigenetic alterations in cancer.

Cold Spring Harbor symposia on quantitative biology·2011
Same author

Loss of a single Hic1 allele accelerates polyp formation in Apc(Δ716) mice.

Oncogene·2011

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • DNA methylation alterations are frequent in human neoplasia.
  • Hypermethylation of gene promoters is common in hematopoietic neoplasms, often leading to gene silencing.
  • This epigenetic silencing affects genes regulating hematopoietic cell growth and differentiation, such as the estrogen receptor (ER) gene, P15, and P16.

Purpose of the Study:

  • To investigate the role and implications of DNA methylation changes in human neoplasia, particularly hematopoietic malignancies.
  • To explore the potential of DNA methylation as a biomarker for disease monitoring and detection.
  • To assess the therapeutic potential of targeting DNA methylation in leukemia.

Main Methods:

  • Analysis of DNA methylation patterns in gene promoters within neoplastic cells.

Related Experiment Videos

  • Identification of specific genes affected by hypermethylation during leukemogenesis.
  • Evaluation of novel technologies for sensitive detection of gene hypermethylation.

    • Main Results:

    • Hypermethylation-associated gene silencing is prevalent in hematopoietic neoplasms.
    • Specific genes like ER, P15, P16, HIC1, and c-abl are affected by methylation.
    • Methylation can occur early in pathogenesis or during disease progression.
    • New technologies enable sensitive detection of gene hypermethylation.

    Conclusions:

    • DNA promoter hypermethylation is a significant molecular abnormality in human neoplasia, especially leukemia.
    • Methylation patterns can serve as biomarkers for monitoring disease activity and detecting minimal residual disease.
    • Pharmacologic inhibition of DNA methyltransferase offers a promising therapeutic strategy for acute leukemia by reactivating tumor-suppressor genes.